MX2022013753A - Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. - Google Patents
Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.Info
- Publication number
- MX2022013753A MX2022013753A MX2022013753A MX2022013753A MX2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- treatment
- amino acid
- acid compounds
- respiratory diseases
- Prior art date
Links
- -1 amino acid compounds Chemical class 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021674P | 2020-05-07 | 2020-05-07 | |
| PCT/US2021/030363 WO2021225912A1 (en) | 2020-05-07 | 2021-04-30 | Treatment of respiratory diseases with amino acid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013753A true MX2022013753A (es) | 2023-01-30 |
Family
ID=78468277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013753A MX2022013753A (es) | 2020-05-07 | 2021-04-30 | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181546A1 (https=) |
| EP (2) | EP4520329A3 (https=) |
| JP (1) | JP2023524970A (https=) |
| KR (1) | KR20230049584A (https=) |
| CN (1) | CN115989235A (https=) |
| AU (1) | AU2021268889A1 (https=) |
| CA (1) | CA3173761A1 (https=) |
| IL (1) | IL297969A (https=) |
| MX (1) | MX2022013753A (https=) |
| WO (1) | WO2021225912A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| EP4247472A4 (en) * | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| MX2023012794A (es) * | 2021-04-30 | 2023-12-15 | Pliant Therapeutics Inc | Regímenes de dosificación expandidos para inhibidores de integrina. |
| CN120091811A (zh) * | 2022-07-09 | 2025-06-03 | 普利安特治疗公司 | 整合素抑制剂及其与其它药剂组合的用途 |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE511850T1 (de) * | 1997-08-08 | 2011-06-15 | Univ California | Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin |
| DE10204789A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta6 |
| US9790222B2 (en) * | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| BR112017023432A2 (pt) * | 2015-04-30 | 2018-07-24 | Scifluor Life Sciences Inc | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo |
| US10118929B2 (en) * | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| BR112021006622A2 (pt) * | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
-
2021
- 2021-04-30 CN CN202180048580.XA patent/CN115989235A/zh not_active Withdrawn
- 2021-04-30 EP EP25152378.3A patent/EP4520329A3/en not_active Ceased
- 2021-04-30 KR KR1020227042773A patent/KR20230049584A/ko active Pending
- 2021-04-30 MX MX2022013753A patent/MX2022013753A/es unknown
- 2021-04-30 JP JP2022567249A patent/JP2023524970A/ja not_active Withdrawn
- 2021-04-30 AU AU2021268889A patent/AU2021268889A1/en not_active Abandoned
- 2021-04-30 IL IL297969A patent/IL297969A/en unknown
- 2021-04-30 WO PCT/US2021/030363 patent/WO2021225912A1/en not_active Ceased
- 2021-04-30 US US17/923,899 patent/US20230181546A1/en not_active Abandoned
- 2021-04-30 EP EP21799675.0A patent/EP4146264A4/en not_active Withdrawn
- 2021-04-30 CA CA3173761A patent/CA3173761A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4520329A2 (en) | 2025-03-12 |
| CN115989235A (zh) | 2023-04-18 |
| KR20230049584A (ko) | 2023-04-13 |
| AU2021268889A1 (en) | 2022-12-15 |
| EP4146264A1 (en) | 2023-03-15 |
| CA3173761A1 (en) | 2021-11-11 |
| US20230181546A1 (en) | 2023-06-15 |
| EP4146264A4 (en) | 2024-07-24 |
| EP4520329A3 (en) | 2025-05-14 |
| WO2021225912A1 (en) | 2021-11-11 |
| JP2023524970A (ja) | 2023-06-14 |
| IL297969A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013753A (es) | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20210224A (es) | Compuestos de amoniácidos y métodos de uso | |
| EP4509512A3 (en) | Amino acid compounds and methods of use | |
| JOP20200154B1 (ar) | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 | |
| MX2020007944A (es) | Nanocomplejos similares a los lípidos y sus usos. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| PH12021552881A1 (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| MX2023004149A (es) | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso. | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA201700077A1 (ru) | Соединения аминопиримидинила в качестве ингибиторов jak | |
| EA201991615A1 (ru) | Композиция маннуроновой дикислоты | |
| WO2010088000A3 (en) | Antifibrotic compounds and uses thereof | |
| DOP2003000678A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| PH12021550767A1 (en) | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation | |
| MX2024004438A (es) | Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes. | |
| CR20230553A (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| GEP20247670B (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| PH12021552533A1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| TW200639159A (en) | Treatment of pain | |
| MX2020004588A (es) | Inhibidor de proteasa de doble cabeza. | |
| NO20065078L (no) | Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister. | |
| NO20070952L (no) | Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike |